Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

Nicolas Folschweiller, Ulrich Behre, Marc Dionne, Paolo Durando, Susanna Esposito, Linda Ferguson, Murdo Ferguson, Peter Hillemanns, Shelly A. McNeil, Klaus Peters, Brian Ramjattan, Tino F. Schwarz, Khuanchai Supparatpinyo, Pemmaraju V. Suryakirian, Michel Janssens, Philippe Moris, Annabelle Decreux, Sylviane Poncelet, Frank Struyf

Research output: Contribution to journalArticle

Abstract

This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following 3 doses in women aged 15-25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.

Original languageEnglish
Pages (from-to)1799-1803
Number of pages5
JournalThe Journal of infectious diseases
Volume219
Issue number11
DOIs
Publication statusPublished - May 5 2019

Fingerprint

Human papillomavirus 31
Human papillomavirus 18
Human papillomavirus 16
Appointments and Schedules
Vaccines
Antibodies
Vaccination
B-Lymphocytes
Clinical Trials
T-Lymphocytes

Keywords

  • AS04-HPV-16/18 vaccine
  • cross-reactivity
  • HPV-31
  • HPV-45
  • immunogenicity
  • nonvaccine types

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine. / Folschweiller, Nicolas; Behre, Ulrich; Dionne, Marc; Durando, Paolo; Esposito, Susanna; Ferguson, Linda; Ferguson, Murdo; Hillemanns, Peter; McNeil, Shelly A.; Peters, Klaus; Ramjattan, Brian; Schwarz, Tino F.; Supparatpinyo, Khuanchai; Suryakirian, Pemmaraju V.; Janssens, Michel; Moris, Philippe; Decreux, Annabelle; Poncelet, Sylviane; Struyf, Frank.

In: The Journal of infectious diseases, Vol. 219, No. 11, 05.05.2019, p. 1799-1803.

Research output: Contribution to journalArticle

Folschweiller, N, Behre, U, Dionne, M, Durando, P, Esposito, S, Ferguson, L, Ferguson, M, Hillemanns, P, McNeil, SA, Peters, K, Ramjattan, B, Schwarz, TF, Supparatpinyo, K, Suryakirian, PV, Janssens, M, Moris, P, Decreux, A, Poncelet, S & Struyf, F 2019, 'Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine', The Journal of infectious diseases, vol. 219, no. 11, pp. 1799-1803. https://doi.org/10.1093/infdis/jiy743
Folschweiller, Nicolas ; Behre, Ulrich ; Dionne, Marc ; Durando, Paolo ; Esposito, Susanna ; Ferguson, Linda ; Ferguson, Murdo ; Hillemanns, Peter ; McNeil, Shelly A. ; Peters, Klaus ; Ramjattan, Brian ; Schwarz, Tino F. ; Supparatpinyo, Khuanchai ; Suryakirian, Pemmaraju V. ; Janssens, Michel ; Moris, Philippe ; Decreux, Annabelle ; Poncelet, Sylviane ; Struyf, Frank. / Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine. In: The Journal of infectious diseases. 2019 ; Vol. 219, No. 11. pp. 1799-1803.
@article{4bbd33b8a9ce45fb851b8a25e9179531,
title = "Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine",
abstract = "This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following 3 doses in women aged 15-25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.",
keywords = "AS04-HPV-16/18 vaccine, cross-reactivity, HPV-31, HPV-45, immunogenicity, nonvaccine types",
author = "Nicolas Folschweiller and Ulrich Behre and Marc Dionne and Paolo Durando and Susanna Esposito and Linda Ferguson and Murdo Ferguson and Peter Hillemanns and McNeil, {Shelly A.} and Klaus Peters and Brian Ramjattan and Schwarz, {Tino F.} and Khuanchai Supparatpinyo and Suryakirian, {Pemmaraju V.} and Michel Janssens and Philippe Moris and Annabelle Decreux and Sylviane Poncelet and Frank Struyf",
year = "2019",
month = "5",
day = "5",
doi = "10.1093/infdis/jiy743",
language = "English",
volume = "219",
pages = "1799--1803",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

AU - Folschweiller, Nicolas

AU - Behre, Ulrich

AU - Dionne, Marc

AU - Durando, Paolo

AU - Esposito, Susanna

AU - Ferguson, Linda

AU - Ferguson, Murdo

AU - Hillemanns, Peter

AU - McNeil, Shelly A.

AU - Peters, Klaus

AU - Ramjattan, Brian

AU - Schwarz, Tino F.

AU - Supparatpinyo, Khuanchai

AU - Suryakirian, Pemmaraju V.

AU - Janssens, Michel

AU - Moris, Philippe

AU - Decreux, Annabelle

AU - Poncelet, Sylviane

AU - Struyf, Frank

PY - 2019/5/5

Y1 - 2019/5/5

N2 - This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following 3 doses in women aged 15-25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.

AB - This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following 3 doses in women aged 15-25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.

KW - AS04-HPV-16/18 vaccine

KW - cross-reactivity

KW - HPV-31

KW - HPV-45

KW - immunogenicity

KW - nonvaccine types

UR - http://www.scopus.com/inward/record.url?scp=85065655508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065655508&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiy743

DO - 10.1093/infdis/jiy743

M3 - Article

C2 - 30715452

AN - SCOPUS:85065655508

VL - 219

SP - 1799

EP - 1803

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 11

ER -